Barclays analyst Gena Wang lowered the firm’s price target on Moderna (MRNA) to $31 from $40 and keeps an Equal Weight rating on the shares. The company’s Q2 outlook cut is due to UK contracting revenue pushed out to Q1 of 2026, the analyst tells investors in a research note. The firm believes Moderna’s further cost cuts will keep its goal intact for breakeven in 2028.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRNA:
- Moderna’s Financial Challenges: Sell Rating Amid Workforce Cuts and Declining Vaccine Revenues
- Moderna’s Financial Outlook: Sell Rating Amid Revenue Challenges and Reliance on COVID-19
- Moderna’s Hold Rating: Navigating Revenue Adjustments and Product Development Uncertainties
- Moderna’s Stock Tumbles Amid Sales Slump and Layoffs
- Moderna’s Q2 2025 Financial Results and Outlook